RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Guangdi Wang to Prodrugs

This is a "connection" page, showing publications Guangdi Wang has written about Prodrugs.
Connection Strength

1.266
  1. Zhong Q, Zhang C, Zhang Q, Miele L, Zheng S, Wang G. Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status. BMC Cancer. 2015 Sep 09; 15:625.
    View in: PubMed
    Score: 0.540
  2. Zhang C, Zhong Q, Zhang Q, Zheng S, Miele L, Wang G. Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer. Breast Cancer Res Treat. 2015 Jul; 152(2):283-91.
    View in: PubMed
    Score: 0.531
  3. Kode NR, Vanden Eynde JJ, Mayence A, Wang G, Huang TL. Design and synthesis of N?,N5-bis[4-(5-alkyl-1,2,4-oxadiazol-3-yl)phenyl]glutaramides as potential antifungal prodrugs. Molecules. 2013 Sep 12; 18(9):11250-63.
    View in: PubMed
    Score: 0.118
  4. Huang TL, Bacchi CJ, Kode NR, Zhang Q, Wang G, Yartlet N, Rattendi D, Londono I, Mazumder L, Vanden Eynde JJ, Mayence A, Donkor IO. Trypanocidal activity of piperazine-linked bisbenzamidines and bisbenzamidoxime, an orally active prodrug. Int J Antimicrob Agents. 2007 Dec; 30(6):555-61.
    View in: PubMed
    Score: 0.078
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support